The meeting serves as the “original”
“I look forward to a great event this year," notes CHI Conference Director, Ming Guo. “I am inspired by the ambitious work from researchers in the SBDD field. CHI & Bio-IT World is honored the industry turns to us every year to organize this conference.”
This event boasts an impressive line-up of leading industry experts including a keynote presentation by Tomi Sawyer, Ph.D., CSO, SVP, Discovery & Innovative Technologies, Aileron Therapeutics. Dr. Sawyer’s presentation, entitled “Drugging the Undruggable:
The International Society for Computational Biology (ISCB) has endorsed its support as a sponsoring society. Due to the overwhelmingly popularity of the Structure-Based Drug Design event, CHI will once again co-locate its Next-Gen Kinase Inhibitors conference to run June 17-19. This gives delegates the unique opportunity to connect with the kinase community and attend the Structure-Based Drug Design event by obtaining an all access, discounted pass.
Early registration discounts will be offered until March 22, 2013. For more details, visit http://www.healthtech.com/
To inquire about sponsoring and/or exhibiting, contact Jon Stroup, 781-972-5483, firstname.lastname@example.org.
Writers and editors are invited to attend. To request a press pass, contact Lisa Scimemi at email@example.com.
About Cambridge Healthtech Institute (chicorporate.com)
Cambridge Healthtech Institute (CHI) is the preeminent life science network for leading researchers and business experts from top pharmaceutical, biotech and academic organizations. CHI’s portfolio of products includes Cambridge Healthtech Institute Conferences, Insight Pharma Reports, Barnett International, Cambridge Marketing Consultants, Cambridge Meeting Planners and Cambridge Healthtech’s Media Group, which includes numerous e-newsletters as well as Bio-IT World magazine.
Founded in 1992, Cambridge Healthtech Institute strives to develop quality information sources that provide valuable new insights and competing points of view while offering balanced coverage of the latest developments. Basic research related to commercial implications is covered, with heavy emphasis placed on end-user insights into new products and technology as well as coverage on the strategy behind the business.
About Bio-IT World: (bio-itworld.com)
Part of the Cambridge Healthtech Institute Media Group (chimediagroup.com)
Cambridge Healthtech Institute